Tranilast
Tranilast is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
200 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Conjunctivitis | D003231 | — | H10 | — | — | — | 1 | — | 1 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | — | — | — | 1 | — | 1 |
| Percutaneous coronary intervention | D062645 | — | — | — | — | — | 1 | — | 1 |
| Rosacea | D012393 | — | L71 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 3 | 1 | — | 2 | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 3 | 1 | — | — | 4 |
| Melanoma | D008545 | — | — | — | 1 | 1 | — | 1 | 3 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | — | 2 | — | — | 2 |
| Gastroenteritis | D005759 | EFO_1001463 | K52.9 | — | 1 | 1 | — | — | 1 |
| Pterygium | D011625 | — | H11.0 | — | — | 1 | — | — | 1 |
| Diabetes insipidus | D003919 | — | E23.2 | — | — | 1 | — | — | 1 |
| Hyponatremia | D007010 | — | E87.1 | — | — | 1 | — | — | 1 |
| Ganglioneuroblastoma | D018305 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 11 | 3 | — | — | — | 13 |
| Healthy volunteers/patients | — | — | — | 8 | 1 | — | — | 1 | 9 |
| Infections | D007239 | EFO_0000544 | — | 5 | 1 | — | — | 2 | 7 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | 4 | — | — | — | 6 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 3 | — | — | 3 | 6 |
| Bronchiolitis obliterans syndrome | D000092122 | — | D89.811 | — | 5 | — | — | — | 5 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 2 | — | — | 1 | 5 |
| Respiration disorders | D012120 | — | J00-J99 | — | 4 | — | — | — | 4 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 2 | — | — | — | 4 |
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
Show 76 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 10 | — | — | — | 1 | 11 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 7 | — | — | — | — | 7 |
| Prostatic neoplasms | D011471 | — | C61 | 5 | — | — | — | 1 | 6 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | — | — | — | — | 3 |
| Positron emission tomography computed tomography | D000072078 | — | — | 3 | — | — | — | — | 3 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | 1 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 2 | — | — | — | — | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 2 | — | — | — | — | 2 |
| Zika virus infection | D000071243 | — | A92.5 | 2 | — | — | — | — | 2 |
| Obstructive lung diseases | D008173 | — | — | 2 | — | — | — | — | 2 |
Show 40 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 3 | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | — | 2 | 2 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 2 | 2 |
| Pediatric obesity | D063766 | — | — | — | — | — | — | 2 | 2 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | — | — | — | 2 | 2 |
| Sleep | D012890 | GO_0030431 | — | — | — | — | — | 2 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 2 | 2 |
| Overweight | D050177 | — | E66.3 | — | — | — | — | 2 | 2 |
| Urologic neoplasms | D014571 | — | C64-C68 | — | — | — | — | 1 | 1 |
Show 81 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tranilast |
| INN | tranilast |
| Description | Tranilast is an amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group. It has a role as an anti-asthmatic drug, a nephroprotective agent, an anti-allergic agent, a calcium channel blocker, an antineoplastic agent, an aryl hydrocarbon receptor agonist and a hepatoprotective agent. It is a member of cinnamamides, a dimethoxybenzene, an amidobenzoic acid and a secondary carboxamide. It is functionally related to an anthranilic acid. |
| Classification | Small molecule |
| Drug class | antiasthmatics/antiallergics (not acting primarily as antihistamines) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC |
Identifiers
| PDB | — |
| CAS-ID | 53902-12-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL415324 |
| ChEBI ID | 77572 |
| PubChem CID | 5282230 |
| DrugBank | — |
| UNII ID | HVF50SMY6E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use